Gunderson Dettmer represented client Contineum Therapeutics, a clinical stage biopharmaceutical company, in its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share. The shares will be traded under the ticker symbol “CTNM.” Contineum is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need.

Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.

The Gunderson Dettmer team was led by Jeff Thacker, Ryan Gunderson, Leanne Gould and Alex Lee.

Companies
Contineum Therapeutics